To our knowledge, this is the first report that analyzes changes in tumor milieu in early non-HER2 overexpressing BC patients treated with NAC ± immunotherapy and identifies good responders to the experimental therapy based on CD8 expression in the needle core biopsy, with an established 4% cut-off point. The gene discussed is ERBB2; the disease is neoplasm.